Viewing StudyNCT00001042



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00001042
Status: COMPLETED
Last Update Posted: 2021-11-04
First Post: 1999-11-02

Brief Title: A Phase I Randomized Double-Blind Placebo-Controlled Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120HIV-1SF2 BIOCINE Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Conditions & Keywords Data

Conditions:
Name
HIV Infections
Keywords:
Name View
HIV Preventive Vaccine View
Vaccines Synthetic View
Drug Therapy Combination View
Adjuvants Immunologic View
HIV Envelope Protein gp120 View
Acetylmuramyl-Alanyl-Isoglutamine View
monophosphoryl lipid A View
AIDS Vaccines View
HIV Seronegativity View